Urokit 10- Potassium citrate 1080mg/tablet (wax matrix extended release tablet).
Mode of action: Kidney stones are formed by crystallization of calcium and other salts present in acidic urine. Once a person has a kidney stone, their chance of getting another one ranges from 65% to 90%. Potassium citrate urokit has developed to prevent further stone formation. When Urokit is given orally, the metabolism of absorbed citrate produces an alkaline load may lead to increase urinary pH to 7.0 and produced a sustained increase in urinary citrate excretion from low values to within normal limits. The absorbed citrate binds to calcium in the urine and hence preventing the calcium from crystallizing and developing into a stone. Again, the rise in urinary pH increases the ionization of uric acid to more soluble urate ion, reducing the risk of developing uric acid stone.
Urokit utilizes a wax-matrix delivery system.
This wax-matrix system delivers a slow, sustained release of medication that allows- convenient dosing, less gastrointestinal upset and enhanced patient compliance. Demonstrates outstanding success: Urokit is clinically proven to inhibit the formation of most kidney stones. Ind: Prevention of repeated kidney stone formation.
C/I; S/E; Precautions: See manufacturer's literature.
Use & admin: Consult manufacturer's literature; (not provided by the authority).
Urokit 10 x 15's pack: 150.00 MRP